Moteur de recherche d’entreprises européennes
Financement de l’UE (4 887 345 €) : Développement d’un écosystème de diagnostic mondial pour la détection et la surveillance des agents pathogènes sujets aux situations d’urgence pour toutes les … Hor01/12/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Développement d’un écosystème de diagnostic mondial pour la détection et la surveillance des agents pathogènes sujets aux situations d’urgence pour toutes les espèces et de manière unifiée
We aim to contribute to global diagnostics and preparedness for the next health crisis by developing in vitro diagnostic devices and methodologies for application at the point-of-care. For this purpose, mature as well as novel technologies and assays will be developed, addressing all pandemic preparedness requirements; i.e., with regards to assay characteristics and ability to assimilate new targets as well as platform ease of use and connectivity fulfilling manufacturing and regulatory requirements. In the 36 months of the project, we intend to develop and deliver two IVDR certified devices and six molecular assays for emerging pathogens detection at the point-of-care. We will build on a recent commercial success during the COVID-19 pandemic, the Pebble platform and an innovative pocket-size device to be developed within the project, both providing capability for connectivity and surveillance. For the RNA-targets detection, we will employ a recently developed amplification method (DAMP) demonstrated to have a high specificity in crude samples. Three broad assays will be developed for screening of viruses belonging in one of the families of Corona, Influenza or Arboviruses, and three specific ones for Dengue, Zika and West Nile viruses, all according to IVDR-recommendations. Importantly the above six assays will be tested using samples from humans, animals and during field-monitoring of mosquito populations, providing a solution for the One Health initiative. For the development of accessible diagnostic tools, the UniHealth consortium consist of expert researchers, technologists, doctors, social scientists, regulators, innovators and biomedical device providers within the areas of diagnostics and pandemics. The high degree of UniHealth’s innovation and the co-development of solutions with global partners and end-users will expand the visibly and uptake of the project results to a global level leading to a high preparedness and an economic and social success.
| PKNM SOLUTIONS Sàrl | ? |
| Biopix DNA Technology Anonymi Etairia | 924 000 € |
| CHARITE - UNIVERSITAETSMEDIZIN BERLIN | 468 263 € |
| Elliniki Enosi Biotechnologias Astiki Mi Kerdoskopiki Etairia | 219 375 € |
| Haraldsplass Diakonale Sykehus AS | 465 731 € |
| Idryma Technologias Kai Erevnas | 1 283 489 € |
| Institut Pasteur | 450 594 € |
| Institut Pasteur DE Tunis | 568 750 € |
| Kiara Health (PTY) Ltd. | 146 101 € |
| Universitetet I Bergen | 361 043 € |
https://cordis.europa.eu/project/id/101137092
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : PKNM Solutions Sàrl, Colombier, Suisse.